That’s the lenient interpretation I’d hope.
But we’re not an alternative medicine group or anything. If you look into their shareholder meetings the public info seems to be that they judge whether investments are worth it by potential return on investment, and well a lifelong treatment is always going to be more profitable for them than a cure.
Crispr is the exception:
Most proposals for cures are a fairly simple (and cheap) therapeutic target that will only work for one condition or even just a subset of cases within that condition.